H.C. Wainwright maintains target for NovaBridge Biosciences stock

Published on 10/05/2026 at 07:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright kept a USD 9.00 target on September 22, 2026. NovaBridge Biosciences stock has USD 156.2 million market value.

NBP, US44975P1030, Illustration mit AI erstellt.

H.C. Wainwright maintained a Buy rating and a USD 9.00 price target for NovaBridge Biosciences stock on September 22, 2026, according to Moomoo. The analyst view puts the target 32.55 percent above the stock's USD 6.79 52-week high.

Pipeline strategy remains central

NovaBridge Biosciences is a clinical-stage biopharmaceutical company developing medicines for oncology and ophthalmology, according to its investor-relations page. The pipeline includes givastomig, a CLDN18.2 x 4-1BB bispecific antibody, Ragistomig, a PD-L1 x 4-1BB bispecific antibody, and Uliledlimab, an anti-CD73 monoclonal antibody.

The same company page identifies VIS-101 as the lead asset of its Visara ophthalmology subsidiary. The program is designed around a VEGF-A and ANG2 bispecific antibody for retinal vascular diseases, giving the company exposure beyond oncology.

Board change adds healthcare experience

NovaBridge appointed Martin Dewhurst as an independent director and member of its Audit and Compensation Committees effective September 8, 2026, as GlobeNewswire reported. The release described Dewhurst as a healthcare executive with more than 30 years of board and senior leadership experience across biotechnology, biopharmaceuticals, medical devices, health technology and healthcare investment.

The appointment followed the departure of independent director Liu Xin. For the company, the change adds governance experience while management continues to advance clinical assets and pursue partnerships.

Market value stays below target

NovaBridge Biosciences had a market capitalization of USD 156.2 million as of October 2, 2026. Its 52-week range was USD 1.31 to USD 6.79 on the same date, while the USD 9.00 analyst target stood 32.55 percent above the upper end of that range.

The valuation gap reflects the market's focus on clinical execution rather than current commercial scale. The company describes its strategy as a hub-and-spoke platform linking Asian innovation with global development and commercialization opportunities.